Loading...
Market
Will Novavax's updated Nuvaxovid COVID-19 vaccine for JN.1 strain receive FDA approval by end of 2024?
4
Resolution / Starting Odds
Yes • 50%
No • 50%
FDA official announcements and press releases
Story
Novavax's Shares Rise as EU Authorizes Updated Nuvaxovid COVID-19 Vaccine Targeting JN.1 Strain
Oct 9, 2024, 12:30 PM
Novavax Inc.'s updated 2024-2025 Nuvaxovid COVID-19 vaccine has received authorization from the European Commission, the company announced on Wednesday. The vaccine, which targets the JN.1 strain of the coronavirus, is approved for preventing COVID-19 in individuals aged 12 years and older across the European Union. Following the news, Novavax's shares rose 3.2% in premarket trading.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Very Positive • 25%
Somewhat Positive • 25%
Neutral • 25%
Negative • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
